SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a focal point for community debate, as traders weigh the potential for a rebound against long-standing skepticism regarding its ecosystem development and burn mechanisms. While some participants are actively accumulating in hopes of a future rally, others express deep frustration, citing the lack of significant price appreciation and calling into question the project's long-term utility.

Anthropic

Anthropic is trending as it rapidly expands its computing infrastructure through major deals with SpaceX and AMD, while aggressively competing in the enterprise AI space with its latest Claude models. The community remains focused on the company's valuation trajectory, high infrastructure spending, and the intense race to maintain a competitive advantage against other frontier AI labs ahead of a potential IPO.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

Technology sector funds like XLK are facing heightened volatility as investors pivot from broad AI spending excitement to demanding concrete evidence of revenue and margin growth. The market is currently grappling with a rotation toward defensive sectors and financials, leaving tech at a pivotal technical test as traders weigh AI-driven cloud demand against concerns over elevated valuations and the impact of evolving U.S. trade policy.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as the community remains deeply divided between long-term investors adding to their positions during market-wide dips and skeptics who frequently label the project a scam due to its stagnant performance and perceived lack of utility. Traders are currently focused on technical resistance levels and debating whether the recent launch of related ecosystem projects indicates abandonment of the main token or a broader strategic expansion.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense selling pressure, leading to community-wide anxiety as the token trends toward multi-year lows despite its enterprise use cases. While some investors are aggressively accumulating to lower their cost basis, others are voicing deep frustration and skepticism regarding the project's long-term viability compared to other major crypto assets.

OpenAI

OpenAI is trending as investors monitor the company's path toward a highly anticipated IPO, with the market closely tracking reports of potential government equity stakes and ongoing competitive pressure from Anthropic. The conversation is heavily focused on the sustainability of the company's massive data center infrastructure spending and the strategic implications of its shifting partnerships in the broader AI sector.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as it faces a high-stakes legal challenge from 12 state attorneys general attempting to block its $110 billion merger with Warner Bros. Discovery despite prior federal approval. Community discussion is polarized, with many investors viewing the lawsuit as politically motivated theater while others express significant concern over the potential for costly ticking fees and further financial strain on the company.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining momentum as investors weigh its shift toward a paid subscription model for data feeds against the broader potential of its oracle services in the RWA and AI sectors. The community is actively debating the project's long-term utility and competitive positioning against incumbents while closely monitoring institutional adoption developments.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is currently trending as investors focus on its strong commercial growth and the upcoming launch of its new oncology asset, VEPPANU, which has bolstered the long-term outlook for its diversified portfolio. Despite recent price volatility, the community is actively debating potential short-covering pressure and the company's attractive valuation relative to its growing revenue streams and profitable operations.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG is trending as investors debate its long-term potential as a Bitcoin-native asset versus its recent price volatility, with the community actively split between loyalists holding for the long haul and skeptics voicing concerns over market manipulation. Discussions remain heavily focused on its structural alignment with the Bitcoin network and the ongoing battle between community-driven conviction and broader market pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress

Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress...

Why Is Legend Biotech Stock Falling Thursday?

Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.read more...

Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in pre-market trading.read more...

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets.read...

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech Q1 Earnings Call Highlights...

Legend Biotech (LEGN) Projected to Post Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Zurcher Kantonalbank Zurich Cantonalbank Decreases Stake in Legend Biotech Corporation Sponsored ADR $LEGN

Zurcher Kantonalbank Zurich Cantonalbank lowered its stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 89.4% in the fourth quarter, according to the company in its most...

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen research firms that are currently covering the...

Legend Biotech Corporation Sponsored ADR $LEGN Stock Holdings Lowered by Matthews International Capital Management LLC

Matthews International Capital Management LLC reduced its holdings in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 7.0% during the 4th quarter, according to its most recent...

Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?

Legend Biotech (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

LEGN Stock Clocks Best Day In Three Years — What’s Driving The Rally?

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.06	--	--	N/A
Q1 '26	$0.01	-$0.15	-1320.60%	MISSED
Q4 '25	$0.04	-$0.08	-323.83%	MISSED
Q3 '25	-$0.07	-$0.11	-51.30%	MISSED
Q2 '25	-$0.12	-$0.34	-195.59%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

LEGNLegend Biotech

Upcoming Earnings: Q2 '26

Historical Earnings

Latest LEGN News